The $865B Opportunity: Why Quality Data is the Foundation of Next-Gen Antibody Development
This report is published by Patsnap.
The antibody therapeutics market is projected to reach $865 billion by 2032, yet R&D teams face major hurdles due to fragmented, low-quality, and biased data. Patsnap’s Lao Tzu Antibody-Antigen Dataset provides a curated solution with 120,000+ antibody-antigen pairs, 20,000+ affinity measurements, and 24,000+ potency values. This resource enables robust AI/ML model training, accelerates target validation, and reduces failed candidates, helping organizations compress months of lab work into weeks of computational analysis. By addressing the data scarcity problem, Lao Tzu positions researchers to lead in next-gen antibody discovery.
Power your next breakthrough with the Lao Tzu dataset—contact Patsnap today.
Patsnap empowers global IP and R&D leaders with AI-augmented intelligence solutions, so they can make high-impact innovation decisions.
White Paper from 